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The reduced maximal exercise capacity of patients with 
heart failure has been attributed to skeletal muscle under-
perfusion with resultant intramuscular lactic acidosis and 
muscular fatigue. To investigate this hypothesis, the effect 
of dichloroacetate, a drug that decreases lactate formation 
by increasing pyruvate oxidation, on the maximal exercise 
performance of 18 patients with heart failure and reduced 
ejection fraction (25 ± 9%) was examined. Exercise tests 
after parenteral dextrose (control) and dichloroacetate 
were performed 1 week apart. The sequence of interven-
tions was randomized in a double-blind manner. 
Dichloroacetate decreased blood lactate at rest (control 
8.0 ± 2.5 versus dichloroacetate 5.6 ± 2.9 mg/dl), through-
out exercise and at peak exercise (control 26.0 ± 14.3 
The maximal aerobic exercise capacity of patients with 
chronic heart failure is frequently reduced (1,2). This exer-
cise intolerance is characteristically associated with marked 
leg fatigue, reduced leg blood flow and increased leg lactate 
release (1-3). Therefore, it has been proposed that the 
exercise capacity of patients with heart failure is limited by 
the following sequence of events. During exercise, skeletal 
muscle blood flow is reduced and this muscle underperfusion 
stimulates anaerobic glycolysis, leading to intramuscular 
lactate accumulation and lactate release into the blood. 
Intramuscular lactate accumulation in turn causes muscle 
fatigue and termination of exercise. 
Despite the theoretical attractiveness of this mechanism, 
From the Cardiovascular Section, Department of Medicine, Hospital of 
the University of Pennsylvania, Philadelphia, Pennsylvania. This study was 
supported by Grant RO-1 HL34834 from the National Institutes of Health, 
Bethesda, Maryland. Dr. Wilson is the recipient of Research Career Devel-
opment Award K04 HL01766 from the National Institutes of Health, Be-
thesda. 
Manuscript received April 4, 1988; revised manuscript received June 2, 
1988, accepted July 12, 1988. 
Address for reprints: John R. Wilson, MD, Cardiovascular Section, 3rd 
Floor White Building, Hospital of the University of Pennsylvania, 3400 
Spruce Street, Philadelphia, Pennsylvania 19104. 
©1988 by the American College of Cardiology 
versus dichloroacetate 19.4 ± 10.8) (all P < 0.05). In 
contrast, dichloroacetate had no effect on exercise time 
(control 15.2 ± 6.0 versus dichloroacetate 15.9 ± 6.2 min) 
or peak exercise oxygen consumption (control 1,280 ± 498 
ml/min versus dichloroacetate 1,312 ± 530 ml/min) (both 
p = NS). In six subjects, dichloroacetate also had no effect 
at peak exercise on leg blood flow (control 2.8 ± 1.1 versus 
dichloroacetate 3.0 ± 0.6 liters/min) or femoral oxygen vein 
saturation (control 12.7 ± 4.1% versus dichloroacetate 
12.5 ± 5.7%). 
These data suggest that intramuscular lactate accumu-
lation is not responsible for muscular fatigue during exer-
cise in patients with heart failure. 
(J Am Coil CardioI1988;12:1464-9) 
direct evidence that intramuscular lactic acidosis causes 
muscular fatigue in patients with heart failure is lacking. 
Accordingly, the present study was undertaken to utilize the 
drug dichloroacetate to investigate this issue. Dichloroace-
tate decreases muscle lactate production by stimulating 
pyruvate dehydrogenase, the enzyme that catalyzes the 
rate-limiting step in the oxidation of pyruvate to acetyl-
coenzyme A (4-8). This effect increases pyruvate oxidation 
and thereby reduces the amount of pyruvate available for 
conversion to lactate. Accordingly, we sought to determine 
whether dichloroacetate can improve the maximal exercise 
capacity and blood lactate response to exercise of patients 
with heart failure. If intramuscular lactic acidosis causes 
muscular fatigue in such patients, we reasoned that attenu-
ation of this acidosis should improve their exercise perfor-
mance. A secondary objective of this study was to investi-
gate the effect of dichloroacetate on leg blood flow and 
oxygen extraction to assure that dichloroacetate does not 
directly influence muscle oxygen delivery. 
Methods 
Study patients. Eighteen men with chronic congestive 
heart failure and an average age pfS5 ± 11 years (±SD) were 
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studied. All patients were in New York Heart Association 
functional class II or III and were receiving digoxin and 
diuretics. Six patients were taking captopril and three were 
taking isosorbide dinitrate. All patients had left ventricular 
dysfunction (ejection fraction 25 ± 9%). Peak exercise 
oxygen consumption ('V02) levels averaged 16.1 ± 4.6 mll 
min per kg (range 8.9 to 25.8). Patients were excluded if they 
were limited by angina or had a myocardial infarction within 
the preceding 3 months or had marked ST depression during 
exercise. 
The protocol was approved by the Committee on Studies 
Involving Human Beings at the University of Pennsylvania. 
Written informed consent was obtained from all subjects. 
Protocol. Before the study, all patients underwent maxi-
mal exercise testing to assure familiarity with the exercise 
protocol and with the apparatus used to measure respiratory 
gases. On the day of study, the patient arrived at the exercise 
laboratory in the morning after an overnight fast. A short 
polyethylene catheter was inserted into an antecubital vein 
for blood sampling. Blood was obtained for lactate analysis 
after which the patient received 200 ml of dextrose intrave-
nously over 30 min. In half of the patients, buffered sodium 
dichloroacetate (35 mg/kg) was added to the dextrose. The 
dose was chosen on the basis of prior observations in normal 
subjects and in patients with shock or diabetes mellitus (9-
11). Knowledge of whether the patient received dichloro-
acetate or only dextrose was withheld from both the patient 
and the physician supervising the test. Thirty minutes after 
the infusion was completed, a repeat supine blood sample 
was obtained for lactate concentration. The patient then 
stood on a treadmill. A mouthpiece was inserted for respi-
ratory gas analysis with the use of a SensorMedics Metabolic 
Cart. During the upright rest period, a third blood sample 
was obtained for lactate concentration. 
The patient was then exercised according to a modified 
Naughton protocol (2), each exercise stage lasting 3 min. 
Respiratory gas analysis was performed continuously. Blood 
for lactate analysis was obtained at the end of each work 
load and at peak exercise. A 12 lead electrocardiogram 
(ECG) was monitored continuously. Arterial blood pressure 
was measured with an upper arm cuff sphygmomanometer 
and mean arterial blood pressure was calculated as (diastolic 
pressure + 1/3 [systolic-diastolic pressure]). After exercise 
was completed, the patient was observed for 1 h and then 
sent home. The following week, the patient underwent the 
identical protocol with the alternate agent (dextrose or 
dichloroacetate). On both study days, exercise testing was 
performed at the same time after the administration of the 
intervention. 
Leg blood flow. In 6 of the 18 patients, a femoral vein 
catheter for measuring leg blood flow was inserted instead of 
an antecubital catheter. Leg blood flow was determined by 
the thermodilution method described by 10rfeldt et al. 
(12,13) and previously utilized by our laboratory (1). In brief, 
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femoral vein flow was measured with use of a 50 cm 5F 
thermodilution catheter with the thermistor at 2 cm and the 
injection port 12 cm from the tip. Flow was determined with 
a commercially available thermodilution computer (Elecath) 
after rapid injection of a 2.5 ml iced dextrose bolus injectate. 
Output curves were displayed on a strip chart recorder to 
assure an exponential decay curve. 10rfeldt et al. (13) 
demonstrated that femoral vein flow measured with this 
technique agrees closely with leg flow determined by injec-
tion of indocyanine green into the femoral artery and sam-
pling from the femoral vein. 
In our laboratory, flow determined by the bolus injectate 
technique correlated closely with known flow rates (0.2 to 
6.0 liters/min, r = 0.99) evaluated with a closed loop system 
in which 37°C water was continuously circulated through 7 
mm polyethylene tubing with use of a roller pump. In studies 
in humans, the coefficient of variation of duplicate flow 
measurements made sequentially in patients during the same 
exercise test was 9 ± 10% at rest and 16 ± 12% during 
exercise. The variation during exercise is expected, given 
the normal phasic alterations in flow. Therefore, multiple 
flow measurements are always made during any given work 
load and the average flow is calculated. During each exercise 
test in this study, each patient underwent 13 to 20 leg blood 
flow measurements, thereby receiving 32 to 50 ml of iced 
dextrose. 
Leg blood flow was measured in triplicate at rest and at 
each work load. Femoral vein blood for lactate concentra-
tion and hemoglobin oxygen (02) saturation measurements 
was also obtained at rest, at the end of each work load and 
at peak exercise. 
Measured variables. Hemoglobin O2 saturation was mea-
sured with an Instrumentation Laboratories 282 Co-
Oximeter precalibrated with human blood. Blood for lactate 
determination was deproteinized with cold perchloric acid 
and assayed with a spectrophotometric technique (14). 
Statistical results. Values are presented as mean ± SD. 
Differences between measurements made with and without 
dichloroacetate were compared with use of the paired Stu-
dent's t test. A probability of <0.05 was considered signifi-
cant. 
Results 
Patients tolerated dichloroacetate administration with no 
side effects other than mild sleepiness in two patients. 
Effect on blood lactate and exercise performance (Table 1, 
Fig. 1). On the day of control exercise, blood lactate aver-
aged 8.6 ± 2.0 mg/dl at supine rest and remained essentially 
unchanged after glucose infusion (7.7 ± 2.4 mg/dl) and when 
the patients stood erect on the treadmill (8.0 ± 2.5 mg/dl). 
During exercise, patients were able to perform for 14.2 ± 5.7 
min to a peak exercise V02 of 1,280 ± 498 mllmin. Blood 
lactate increased progressively to a peak level of 28.4 ± 12.7 
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Table 1. Effect of Dichloroacetate on Exercise Performance in 18 
Patients With Chronic Heart Failure 
Rest Peak Exercise 
Control Dichloroacetate Control Dichloroacetate 
Exercise duration 14.2 ± 5.7 14.7 ± 5.5 
(min) 
V02 (ml/min) 311 ± 90 308 ± 68 1,280 ± 498 1,312 ± 530 
Heart rate 85 ± 16 86 ± 13 140 ± 22 140 ± 22 
(beats/min) 
Mean arterial 96 ± 12 92 ± 13 III ± 23 112 ± 19 
pressure 
(mmHg) 
mg/dl. At peak exercise, patients reported both leg fatigue 
and dyspnea but identified fatigue as the major limiting 
symptom. 
On the day of dichloroacetate administration, blood 
lactate initially was 8.7 ± 2.8 mg/dl, a level not significantly 
different from levels noted on the control exercise day. 
Administration of dichloroacetate decreased lactate to 6.1 ± 
2.7 mg/dl, reflecting an average decrease of 34 ± 22%. When 
the patients stood on the treadmill, lactate remained de-
pressed at 5.6 ± 2.9 mg/dl (p < 0.03 versus control exercise). 
Blood lactate also remained depressed throughout exercise. 
Despite this reduction in lactate, the heart rate and blood 
pressure responses to exercise were comparable with levels 
noted during control exercise. Patients reported no change in 
the extent of leg fatigue experienced during exercise. Peak 
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Figure 1. Effect of dichloroacetate (DICHLORO) on blood lactate 
concentration at supine rest before dichloroacetate or glucose 
administration (S), after the intervention (I) and during treadmill 
exercise in 18 patients. 
exercise V02 (1,312 ± 530 mllmin) and exercise duration 
(14.7 ± 5.5 min) were also unchanged from control exercise. 
Effects on respiratory gases (Fig. 2). During control exer-
cise, V02 increased progressively throughout exercise. Car-
bon dioxide production (VC02) and minute ventilation (V E) 
increased out of proportion to V02 after 6 min of exercise 
accompanied by an increase in the respiratory gas exchange 
ratio, consistent with achievement of the ventilatory lactate 
threshold. After administration of dichloroacetate, respira-
tory gas exchange levels at rest and during exercise were 
comparable with levels noted during the control study. 
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Figure 2. Effect of dichloroacetate 
(DICHLORO) on minute oxygen con-
sumption (V02), minute carbon diox-
ide production (VCOz), minute ventila-
tion (V E) and the respiratory gas 
exchange ratio (RER) during exercise 
in 18 patients. 
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Figure 3. Effect of dichloroacetate (DICHLORO) on leg blood flow 
and femoral venous oxygen (02) saturation during treadmill exercise 
in six patients. 
Effect on leg blood flow (Fig. 3). Leg blood flow measure-
ments were made in 6 of the 18 patients. Leg blood flow at 
supine rest averaged 0,4 ± 0.2 liters/min and increased 
progressively during exercise to a peak level of 2.8 ± 1.1 
liters/min. Femoral vein O2 saturation decreased from 57 ± 
14 to 13 ± 5%. After dichloroacetate administration, leg 
blood flow at rest averaged 0.5 ± 0.3 liters/min and increased 
to 2.9 ± 0.7 liters/min at peak exercise, a value not signifi-
cantly different from that at control exercise. Femoral vein 
O2 saturation was also not significantly different from levels 
noted during control exercise. 
Discussion 
Objectives of the study. The present study was under-
taken to determine whether intramuscular lactic acidosis 
produces muscular fatigue in patients with heart failure. To 
this end, we examined the effect of dichloroacetate on the 
maximal exercise performance of a group of ambulatory 
patients with heart failure; maximal exercise in such patients 
is typically limited by fatigue (1-3). 
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Dichloroacetate reduces lactate formation in normal mus-
cle by stimulating the activity of pyruvate dehydrogenase, 
the rate-limiting enzyme in the oxidation of pyruvate (4--8). 
Pyruvate dehydrogenase exists in two forms: an inactive 
phosphorylated and an active de phosphorylated form. In 
rest muscle, only approximately 15 to 20% of the total 
pyruvate dehydrogenase is in the active state (15,16). Exer-
cise can increase this proportion as high as 40 to 50% (15,16). 
Dichloroacetate appears to be able to increase this propor-
tion still further, thereby reducing levels of all the principal 
glycolytic byproducts including lactate and pyruvate. For 
example, Merrill et al. (7) demonstrated that dichloroacetate 
can reduce blood lactate levels in exercising dogs by >50%. 
Schneider et al. (6) demonstrated approximately a 30% 
reduction in muscle lactate concentration in exercising rats. 
Loubatieres et al. (8) noted that dichloroacetate reduced the 
lactate concentration in venous blood leaving the contracting 
dog hind limb from 55 to 15 mg/dl. 
An additional objective of this study was to investigate 
the effect of dichloroacetate on muscle oxygen delivery. 
Although prior observations suggest that dichloroacetate 
reduces muscle lactate accumulation by stimulating pyru-
vate dehydrogenase, we thought it would be of interest to 
determine whether this drug also augments leg oxygen 
delivery. Leg blood flow was measured with use of a 
thermodilution catheter positioned in the femoral vein. We 
have previously utilized this catheter system in patients 
during upright bicycle exercise and have shown that it 
provides flow values that correlate closely with the level of 
work and that are comparable with leg flow levels measured 
with other techniques (1,12,13). The thermodilution catheter 
technique measures total leg flow and therefore is not a 
direct measure of skeletal muscle flow. Nevertheless, this 
technique does provide a useful index of muscle flow be-
cause the vast proportion of leg flow is distributed to skeletal 
muscle, particularly during exercise. To investigate the 
effect of dichloroacetate on lactate, we measured femoral 
vein lactate in six patients and antecubital vein lactate in the 
remaining patients. Venous lactate was measured rather 
than arterial lactate because both femoral vein and antecu-
bital vein lactate concentration have been shown to parallel 
changes in arterial lactate concentration (17,18). 
Effects of control exercise. During control exercise, pa-
tients exhibited reduced peak exercise V02 levels and ele-
vated blood lactate levels. Peak exercise lactate levels were 
comparable with those previously reported from this labora-
tory (1) and by others (2). The respiratory gas exchange ratio 
increased progressively after about 6 min of exercise. This 
phenomenon has been termed the anaerobic or ventilatory 
lactate threshold and has traditionally been attributed to 
bicarbonate buffering oflactate with release of ve02 dispro-
portionate to V02 (2). Leg blood flow and femoral vein O2 
saturation were similar to those previously reported by us in 
patients performing bicycle exercise (1). 
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Effects of dichloroacetate on exercise performance. Ad-
ministration of dichloroacetate decreased blood lactate con-
centration both at rest and throughout exercise. In contrast, 
no change was observed in exercise performance as mea-
sured by exercise time or peak exercise V07 • Respiratory 
gas responses to exercise remained similar to those noted 
during control exercise. Leg blood flow was also unchanged, 
suggesting that dichloroacetate does not alter muscle blood 
flow. Further supporting the absence of any change in 
muscle flow was the absence of any change in femoral vein 
O2 saturation; at any given work load, changes in femoral 
vein O2 saturation should parallel changes in leg flow. 
Similar findings were observed in patients with moderate to 
severe exercise intolerance (peak V02 :S 15 mllmin per kg) 
and patients with less marked exercise intolerance (peak 
V07 > 15 mllmin per kg). 
Role of intramuscular lactic acidosis in muscular fatigue. 
These findings suggest that intramuscular lactic acidosis is 
not responsible for muscular fatigue in patients with heart 
failure. On the basis of experimental animal studies (6-8), it 
seems likely that the reduced blood lactate levels noted in 
our patients reflected a reduction in intramuscular lactate 
accumulation. This reduction in intramuscular lactate accu-
mulation should in turn have improved the exercise capacity 
of our patients, if in fact this exercise capacity was limited by 
intramuscular lactic acidosis and consequent muscular fa-
tigue. 
Our conclusion that exertional fatigue in patients with 
heart failure is probably not due to intramuscular lactic 
acidosis is consistent with recent observations concerning 
the mechanism responsible for muscular fatigue in normal 
subjects. In normal subjects, muscular fatigue during stren-
uous exercise has long been attributed to intramuscular 
lactic acidosis (19). However, several recent studies (20-23) 
in humans and experimental animals have suggested that 
muscular fatigue may be due to production of the diproto-
nated acidic form of inorganic phosphate (H2P04 -) rather 
than to lactic acidosis. Therefore, in patients with heart 
failure, it is possible that maximal exercise is limited by 
H2P04 - rather than by lactic acidosis. 
Massie et al. (24) noted a relation between exercise 
intolerance in patients with heart failure and flexor digitorum 
superficialis muscle pH during finger flexion, suggesting that 
exercise intolerance in heart failure may be related to muscle 
pH (24). This finding is not necessarily incompatible with the 
results of the present study. Demonstration of a relation 
between muscle pH and fatigue does not necessarily indicate 
cause and effect. For example, we recently noted (23) a close 
linear relation between forearm muscle pH and forearm 
muscle fatigue during maximal forearm exercise. However, 
reduction of forearm muscle pH by prior submaximal fore-
arm exercise had no effect on muscle fatigue during maximal 
exercise. 
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Possible limitations of study. Our study does not totally 
exclude the possibility that intramuscular lactic acidosis 
produces muscular fatigue in heart failure. It demonstrates 
that dichloroacetate can reduce blood lactate levels during 
exercise. Although this reduction in blood lactate appears to 
reflect a reduction in muscle lactate production, blood 
lactate is also influenced by lactate extraction. It is possible 
that dichloroacetate reduced blood lactate levels in our study 
primarily by increasing lactate extraction rather than by 
decreasing lactate production. Moreover, even if the reduc-
tion in blood lactate was due entirely to reduced muscle 
lactate production, sufficient intramuscular lactate produc-
tion may have occurred after dichloroacetate administration 
to interfere with muscle performance. Conceivably, admin-
istration of a higher dose of dichloroacetate than that given 
in our study could produce a greater reduction in lactate 
production. In this study, we chose not to use a higher 
dichloroacetate dose to minimize potential side effects. 
Because the only side effect observed was mild sleepiness in 
two patients, it is likely that a higher dose of dichloroacetate 
could be administered without problems. 
Two further issues should also be considered in interpret-
ing this study. It is important to establish that the population 
size used in this study was sufficient to detect an effect of 
dichloroacetate on exercise V02. The population size was 
sufficient to detect a 10% change in V02 with a power of 
>0.90 (25), making it unlikely that a beta error occurred. It 
is also important to note that patients in this study experi-
enced exertional dyspnea during exercise. This symptom 
may contribute to their exercise intolerance. Therefore, 
dichloroacetate may not have improved the exercise intoler-
ance of patients because dyspnea rather than fatigue was the 
primary limiting symptom. This factor seems unlikely, how-
ever, because all patients identified muscular fatigue as the 
major limiting symptom. 
A second implication of this study concerns the use of 
blood lactate and respiratory gases to evaluate therapeutic 
regimens in heart failure. We and others (26-30) have 
utilized blood lactate and the ventilatory lactate threshold to 
evaluate the effect of drugs on exercise performance. In 
these studies, it has been assumed that a reduction in blood 
lactate level or the ventilatory lactate threshold, or both, 
indicates improved muscle perfusion. Results of the present 
study indicate that lactate can be reduced without improving 
muscle perfusion, suggesting that changes in blood lactate 
levels observed with therapeutic interventions should be 
interpreted with caution. In addition, the failure of respira-
tory gases to change despite changes in blood lactate indi-
cates that significant changes in lactate in patients with heart 
failure may not be detected by respiratory gas analysis. 
Conclusions. Results of the present study indicate that 
dichloroacetate can be given safely as a single dose to 
patients with heart failure and that this intervention reduces 
blood lactate levels both at rest and during exercise. Dichlo-
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roacetate therefore may provide a useful tool to study lactate 
homeostasis in heart failure. The failure of dichloroacetate to 
improve the exercise performance of patients with heart 
failure suggests that intramuscular lactic acidosis may not 
cause muscular fatigue in such patients. 
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